A randomized, Double blinded, Placebo-Controlled, Researcher clinical Study to Evaluate Efficacy and Safety of Oryung-san Extract Granules in Stage 1 Hypertension Patients without Antihypertensive Medication

INTERVENTION: Drug : Experimental group: Oryung‐san Extract Granule, 2 sachets (3g per sachet), three times daily for 8 weeks Placebo Group: Placebo (without Oryung‐san Extract), 2 sachets (3g per sachet), three times daily for 8 weeks CONDITION: Diseases of the circulatory system PRIMARY OUTCOME: Change in seated systolic blood pressure (SBP) from baseline after 8 weeks of treatment. SECONDARY OUTCOME: Adverse Events Blood Pressure Normalization Rate: Proportion of subjects whose seated SBP is less than 140 mmHg and DBP is less than 90 mmHg after 8 weeks of treatment, relative to baseline. Blood Pressure Response Rate: Proportion of subjects with a decrease in seated SBP of at least 20 mmHg and DBP of at least 10 mmHg from baseline after 8 weeks of treatment. Change in seated diastolic blood pressure (DBP) from baseline after 8 weeks of treatment. Quality of Life Assessment (EQ‐5D) INCLUSION CRITERIA: Adult men and women aged 19 years or older. Individuals whose seated systolic and/or diastolic blood pressure meets either of the following criteria: ‐ 140 mmHg= mean seated systolic blood pressure (MSSBP) = 159 mmHg ‐ 90 mmHg= mean seated diastolic blood pressure (MSDBP) = 99 mmHg Not currently taking any antihypertensive medication, and has not taken antihypertensive medication within the past 4 weeks. Voluntarily signs the informed consent form and does not meet any exclusion criteria.